DeMaubeuge J, Haneke E, Djawari D, Wolff K, Stingl G, Molin L, Schöpf E, Stengel R, Degreef H, Panconesi E
Surv Immunol Res. 1985;4 Suppl 1:30-6.
Twenty-seven patients suffering from long-standing, severe, recurrent herpes simplex (14 labial and 13 genital) who had not responded adequately to prior therapy were recruited for this open, monitored study. They were treated with thymopentin 50 mg subcutaneously three times weekly for a period of 6 weeks. Clinical controls were performed once a week and then again 6 weeks after cessation of therapy; laboratory investigations were done at time points 0, 3, and 6 weeks. Additionally, information was collected with regard to the clinical course during the following year. Thirteen of 14 patients with labial infection and 10 of the 13 with genital herpes improved markedly (p less than 0.05) as shown by decrease in the relapse rate of at least 50%, shorter relapse episodes, and improvement of symptoms such as pain and itching. Fourteen of these 27 patients experienced no relapse for a period longer than 4 months after cessation of therapy. These favorable results were paralleled by a statistically significant increase in the T cell helper/suppressor ratio. This finding indicates that thymopentin acts as an immunodomulator; it is assumed that the activation of T helper cells induces-presumable via interleukin 2-the proliferation of cytotoxic T lymphocytes and natural killer cells which play a major role in the natural immune defense. No serious side effects of thymopentin were recorded.
27例患有长期、严重、复发性单纯疱疹（14例唇疱疹和13例生殖器疱疹）且对先前治疗反应不佳的患者被纳入这项开放、监测的研究。他们接受了胸腺五肽50mg皮下注射，每周3次，共6周。每周进行一次临床对照，治疗停止后6周再次进行；实验室检查在第0、3和6周时间点进行。此外，收集了接下来一年的临床病程信息。14例唇感染患者中有13例，13例生殖器疱疹患者中有10例有明显改善（p<0.05），表现为复发率至少降低50%、复发发作缩短以及疼痛和瘙痒等症状改善。这27例患者中有14例在治疗停止后4个月以上未复发。这些良好结果与T辅助细胞/抑制细胞比值的统计学显著增加相平行。这一发现表明胸腺五肽起免疫调节剂的作用；据推测，T辅助细胞的激活通过白细胞介素2诱导细胞毒性T淋巴细胞和自然杀伤细胞增殖，而这些细胞在天然免疫防御中起主要作用。未记录到胸腺五肽的严重副作用。
